Metformin and Alogliptin

Therapeutic indications

Metformin and Alogliptin is indicated for:

Diabetes mellitus type 2

Population group: only adults (18 years old or older)

Alogliptin/metformin combination is indicated in the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus:

  • as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin.
  • in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone.
  • in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Metformin and Alogliptin is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Acute metabolic acidosis

Metabolic acidosis

Diabetic pre-coma

Coma due to diabetes mellitus

Severe renal failure, GFR <30 ml/min

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Acute conditions with the potential to alter renal function

at least one of
Dehydration
Infectious disease
Shock

Acute or chronic disease which may cause tissue hypoxia

at least one of
Heart failure
Respiratory failure
Myocardial infarction
Shock

Hepatic impairment

Hepatic insufficiency

Acute alcohol intoxication, alcoholism

at least one of
Acute alcohol intoxication
Alcoholism

Iodinated contrast agents

X-ray contrast media, iodinated

Surgery

at least one of
Surgical procedure
General anesthesia
Spinal block
Epidural anesthesia

Sulphonylurea

Sulfonamides, urea derivatives

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: VIPDOMET Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈